{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:47:48Z","timestamp":1773157668354,"version":"3.50.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Nodular sclerosis classical Hodgkin lymphoma (NSCHL) is a rare disease in which Epstein\u2013Barr virus (EBV) and CD20 can be detected. The clinical significance of EBV infection, CD20 expression and their relationship are still unclear in NSCHL presently. The aim of this research was to systematically explore the clinical significance of EBV infection, expression of CD20 and their relationship in NSCHL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>109 NSCHL patients diagnosed in Qingdao University\u2019s Affiliated Hospital were chosen from January 2010 to July 2019, and the clinical and survival data of all patients were collected retrospectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 109 patients, 33 patients were assigned to the group of EBV-positives, following the results of the EBV-encoded RNA (EBER1). Compared with EBV-negative group patients, those in the group of EBV-positive were older (<jats:italic>P<\/jats:italic>=0.004) and their \u03b22-microglobulin (\u03b22-MG) levels were higher (<jats:italic>P<\/jats:italic>=0.006). The CD20 positivity rate in the group of EBV-positive was substantially higher than that in the EBV-negative group (54.5% vs 27.6%, <jats:italic>P<\/jats:italic>=0.007). Among 109 patients, EBV+ and CD20+ double positive patients acquired the least overall survival (OS), and patients with EBV- and CD20- double negative had the best OS (<jats:italic>P<\/jats:italic> &amp;lt; 0.001). Although old age, gender, EBV infection and CD20 positive were the risk factors for OS in NSCHL, multivariate analysis showed that CD20 positivity was the only characteristic that showed to be an independent risk factor for OS in NSCHL patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CD20 was found to be strongly expressed in NSCHL patients who had been infected with EBV, and it was found to be an independent risk factor for NSCHL patients\u2019 survival.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.993768","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T10:13:08Z","timestamp":1662459188000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["CD20 expression is closely associated with Epstein\u2013Barr virus infection and an inferior survival in nodular sclerosis classical Hodgkin lymphoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Xia","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushuo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Bian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihe","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the world health organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1671-2870.2012.02.006","article-title":"Distribution pattern of lymphoma subtypes in China: A nationwide multicenter study of 10002 cases","volume":"11","author":"Li","year":"2012","journal-title":"J Diagn Concepts Pract"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2019.1598678","article-title":"Clinical characteristics and prognostic factors of primary extranodal classical Hodgkin lymphoma: a retrospective study","volume":"24","author":"Yang","year":"2019","journal-title":"Hematology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2009.07.005","article-title":"The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal","volume":"143","author":"Chang","year":"2009","journal-title":"Virus Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/1750-9378-9-38","article-title":"Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010","volume":"9","author":"Khan","year":"2014","journal-title":"Infect Agent Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2016.09.004","article-title":"Prognostic significance of Epstein-Barr virus (EBV) infection in Hodgkin lymphoma patients","volume":"23","author":"Myriam","year":"2017","journal-title":"J Infect Chemother"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/01.MP.0000071843.09960.BF","article-title":"Longer failure-free survival interval of Epstein-Barr virus-associated classical hodgkin's lymphoma: a single-institution study","volume":"16","author":"Krugmann","year":"2003","journal-title":"Mod Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.6310","article-title":"Epstein-Barr Virus as a marker of survival after hodgkin's lymphoma: a population-based study","volume":"23","author":"Keegan","year":"2005","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03815.x","article-title":"Hodgkin's disease in the elderly: a population-based study","volume":"119","author":"Stark","year":"2002","journal-title":"Br J Haematol"},{"key":"B10","article-title":"Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and reed-sternberg cells of classical hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome","volume":"9","author":"Herling","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1309\/MMAU-0QYH-7BHA-W8C2","article-title":"Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma","volume":"117","author":"Gulley","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3960\/jslrt.20010","article-title":"Clinicopathological significance of CD79a expression in classic Hodgkin lymphoma","volume":"60","author":"Sakatani","year":"2020","journal-title":"J Clin Exp Hematop"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2007-1","article-title":"Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma","volume":"104","author":"Makita","year":"2016","journal-title":"Int J Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012120","article-title":"Epidemiologic characteristics of malignant lymphoma in hubei, China: A single-center 5-year retrospective study","volume":"97","author":"Meng","year":"2018","journal-title":"Medicine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.10.010405","article-title":"Risk factors for Epstein Barr virus-associated cancers: a systematic review, critical appraisal, and mapping of the epidemiological evidence","volume":"10","author":"Bakkalci","year":"2020","journal-title":"J Glob Health"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg065","article-title":"The effect of Epstein-Barr virus status on outcome in age- and sex-defined subgroups of patients with advanced hodgkin's disease","volume":"14","author":"Flavell","year":"2003","journal-title":"Ann Oncol"},{"key":"B17","article-title":"Expression of Epstein-Barr virus in classical hodgkin's lymphomas in Brazilian adult patients","volume":"86","author":"Vassallo","year":"2001","journal-title":"Haematologica"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010415)91:8<1579::aid-cncr1169>3.0.co;2-l","article-title":"Epstein-Barr Virus and survival after Hodgkin disease in a population-based series of women","volume":"91","author":"Clarke","year":"2001","journal-title":"Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/028418699431942","article-title":"Epstein-Barr Virus distribution in hodgkin's disease in an unselected Swedish population","volume":"38","author":"Enblad","year":"1999","journal-title":"Acta Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3759","article-title":"Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study","volume":"106","author":"Jarrett","year":"2005","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.5138","article-title":"Latent Epstein-Barr virus infection of tumor cells in classical hodgkin's lymphoma predicts adverse outcome in older adult patients","volume":"27","author":"Diepstra","year":"2009","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.63.09.810","article-title":"CD20 role in pathophysiology of hodgkin's disease","volume":"63","author":"Santos","year":"2017","journal-title":"Rev Assoc Med Bras"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.9881","article-title":"Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome","volume":"31","author":"Greaves","year":"2013","journal-title":"J Clin Oncol"},{"key":"B24","article-title":"Predictive significance of the cut-off value of CD20 expression in patients with b-cell lymphoma","volume":"24","author":"Horvat","year":"2010","journal-title":"Oncol Rep"},{"key":"B25","article-title":"Prognostic significance of CD20 expression in classical Hodgkin lymphoma: a clinicopathological study of 119 cases","volume":"9","author":"Tzankov","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802239170","article-title":"CD20 expression by Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma is related to reduced overall survival in young adult patients","volume":"49","author":"Aldred","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04964.x","article-title":"Adverse prognostic significance of CD20 positive reed-sternberg cells in classical hodgkin's disease","volume":"125","author":"Portlock","year":"2004","journal-title":"Br J Haematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe0912481","article-title":"Toward a personalized treatment of hodgkin's disease","volume":"362","author":"DeVita","year":"2010","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32741","article-title":"Evaluation of the antibody response to the EBV proteome in EBV-associated classical Hodgkin lymphoma","volume":"147","author":"Liu","year":"2020","journal-title":"Int J Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.199844","article-title":"ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study","volume":"104","author":"Strati","year":"2019","journal-title":"Haematologica"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.993768\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T10:13:16Z","timestamp":1662459196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.993768\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":32,"alternative-id":["10.3389\/fonc.2022.993768"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.993768","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"article-number":"993768"}}